We narrowed to 10 results for: 272

#75470-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (#75470). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, Flp recombinase-dependent expression of channelrhodopsin H134R mutant fused to mCherry. These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

March 2, 2020

Academic Institutions and Nonprofits only

#50942-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#50942). In addition to the viral particles, you will also receive purified pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#68719-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6f-WPRE-pA (#68719). In addition to the viral particles, you will also receive purified pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6f-WPRE-pA plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor with bicistronic mRuby2. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

June 5, 2018

Academic Institutions and Nonprofits only

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#68717-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68717). In addition to the viral particles, you will also receive purified pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. CAG-driven, Cre dependent, GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

May 4, 2018

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#75469-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-Flp-DOG-NW (#75469). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flp-DOG-NW plasmid DNA. EF1a-driven expression of Flp recombinase dependent on GFP (Flp-DOG); to be coinjected with GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

Feb. 19, 2020

Academic Institutions and Nonprofits only

#75033-AAV9

Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#85450-AAV8

Ready-to-use AAV8 particles produced from pAAV-RSV-SpCas9 (#85450). In addition to the viral particles, you will also receive purified pAAV-RSV-SpCas9 plasmid DNA. RSV-driven expression of SpCas9. These AAV preparations are suitable purity for injection into animals.

Hetian Lei

Duan et al J Biol Chem. 2016 May 31. pii: jbc.M116.

Jan. 14, 2026

Academic Institutions and Nonprofits only